Canine parvovirus (CPV) type 2a (CPV-2a) has recently been identified as the main genotype circulating in the dog population in South Korea. Although CPV vaccines protect domestic dogs from CPV-2 infection, the efficacy of commercial live or inactivated CPV vaccines against CPV-2a has not been reevaluated. In this study, dogs were immunized with one of 7 commercial CPV vaccines (4 modified live and 3 inactivated vaccines) followed by challenge with CPV-2a strain, KV0901 that had been isolated from naturally infected dog in 2009. All dogs vaccinated twice with 4 commercial modified live CPV vaccines were seroconverted (geometric mean HI titer > 190.2) and most of dogs were completely protected against virulent CPV-2a strain infection. The dogs inoculated with 3 commercial inactivated CPV vaccines were also seroconverted and showed a slight loss of appetite and light diarrhea for 4 days after challenge and returned to normal at 5 days post challenge. However, the non-vaccinated dogs revealed the typical clinical signs of CPV infection including haemorrhgic diarrhea. In conclusion, the 4 live CPV vaccines licensed in Korea cross-protected dogs against virulent challenge with CPV-2a and are applicalble to pet dogs for the prevention of CPV infection.